December 9th 2021
By Tony Hagen
Ahead of sales and revenues, Icelandic company Alvotech lines up a massive capital investment and an initial public offering (IPO).
December 7th 2021
By Deana Ferreri, PhD
In a review, Sandoz researchers discuss lingering barriers that prevent insulin prices from falling to more affordable levels.
December 2nd 2021
By Meir Rinde, MS
Researchers report findings that suggest a different reimbursement system for Medicare Part B biologics could lead to significantly more robust savings.
November 30th 2021
Regulators are at work clarifying biosimilar guidance and on Capitol Hill, a battle is raging over reforms that could help or hurt biosimilar advancement.
November 24th 2021
Authors of a new study estimated significant savings from biosimilars in Ontario based on deep price discounts and mandatory switching programs.
November 23rd 2021
Authors of a review discuss barriers to insulin access and potential solutions as the 100-year anniversary of the drug's first use for diabetes gets closer.
November 13th 2021
Kathy Oubre, MS, a cochair of the biosimilars committee of the Community Oncology Alliance (COA), explains findings from a broad study of biosimilar use in oncology practices.
November 8th 2021
Janet Woodcock, MD, acting commissioner of the FDA, said the agency is meeting with biosimilar developers for biosimilars for 46 reference products.
November 5th 2021
As House leaders sought to build support for the Build Back Better Act, the Association for Accessible Medicines (AAM) objected to drug price negotiations and proposed “rebate penalties.”
November 4th 2021
Prime Therapeutics said that by putting Semglee (insulin glargine) on formulary, along with other biosimilars, it could achieve savings of $41 million or more per year.
